Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.48 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6201870 | 0.87 | MTNR1A (0.51) | CALM1CHRM2CHRM1CHRM3DHFR | |
| SCHEMBL226216 | 0.87 | MAOB (0.56) | CALM1CHRM2CHRM1CHRM3DHFR | |
| SCHEMBL30416326 | 0.85 | ABCB1 (0.62) | ABCB1HTR1ADRD2TAAR1ABCG2 | |
| SCHEMBL4189173 | 0.85 | ABCB1 (0.62) | ABCB1HTR1ADRD2TAAR1ABCG2 | |
| SCHEMBL8702673 | 0.83 | CHRM2 (0.54) | CHRM2CHRM1CHRM3ABCB1HTR1A | |
| SCHEMBL19900978 | 0.83 | ESR1 (0.56) | CHRM2CHRM1CHRM3ABCB1HTR1A | |
| SCHEMBL8607999 | 0.82 | HSPA5 (0.65) | IDO1TAAR1KEAP1HSPA5 | |
| SCHEMBL19900867 | 0.81 | HDAC1 (0.56) | CHRM2CHRM1CHRM3ABCB1HTR1A | |
| SCHEMBL6201740 | 0.81 | CALM1 (0.51) | CALM1CHRM2CHRM1CHRM3DHFR | |
| SCHEMBL19900980 | 0.81 | HDAC1 (0.56) | CHRM2CHRM1CHRM3ABCB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3503879-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva UG (Haftungsbeschränkt) (DE) | 2019-07-03 | — | — | EP | disclosed |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA (UG) (haftungsbeschränkt) (DE) | 2019-06-20 | — | — | US | disclosed |
| CN-109890371-A | Compositions and methods thereof | 斯瑞尼瓦萨饶·韦帕切杜 | 2019-06-14 | — | — | CN | disclosed |
| WO-2018039642-A1 | COMPOSITIONS AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-03-01 | — | — | WO | disclosed |
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| CN-101010276-B | Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same | CHUGAI PHARMACEUTICAL CO LTD | 2011-01-12 | — | — | CN | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| CN-101010276-A | Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-08-01 | — | — | CN | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | CALM1 743/4885CHRM2 836/4885CHRM1 414/4885 |
| US-20190183885-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP11B2, CYP2D6 | CALM1 4224/4885CHRM2 3662/4885CHRM1 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.